KimberlyClark (KMB)
(Delayed Data from NYSE)
$134.61 USD
+0.43 (0.32%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $134.57 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$134.61 USD
+0.43 (0.32%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $134.57 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
ACI vs. KMB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ACI vs. KMB: Which Stock Is the Better Value Option?
Kimberly-Clark (KMB) Hurt by High Costs, Low Tissue Volumes
by Zacks Equity Research
Kimberly-Clark Corporation (KMB) is battling escalated input costs and other manufacturing expenses. Also, consumer tissue volumes declined in the second quarter.
FRG vs. KMB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FRG vs. KMB: Which Stock Is the Better Value Option?
Vista Outdoor, Kimberly-Clark and Tesla highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vista Outdoor, Kimberly-Clark and Tesla highlighted as Zacks Bull and Bear of the Day
Bear Of The Day: KimberlyClark (KMB)
by Brian Bolan
This stock has missed earnings in each of the last two quarters, and estimates are dropping.
New Strong Sell Stocks for July 26th
by Zacks Equity Research
ATHM, CIR, GGAL, HRTG and KMB have been added to the Zacks Rank #5 (Strong Sell) List on July 26, 2021.
Kimberly-Clark (KMB) Cuts 2021 View on Q2 Earnings & Sales Miss
by Zacks Equity Research
Kimberly-Clark's (KMB) second-quarter 2021 results reflect lower earnings due to increased input costs. Management cuts 2021 view for sales, earnings and adjusted operating profit.
Markets Up on Continued Q2 Beats: AmEx, Honeywell & More
by Mark Vickery
On this final trading day of the week, it's almost as if Monday never happened.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Kimberly-Clark (KMB) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Kimberly-Clark (KMB) delivered earnings and revenue surprises of -15.03% and -1.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Kimberly-Clark (KMB) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Kimberly-Clark's (KMB) second-quarter 2021 performance is likely to reflect softness in the K-C Professional unit and higher commodity costs. Nevertheless, saving efforts should offer some respite.
Earnings Preview: Kimberly-Clark (KMB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Kimberly-Clark (KMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kimberly-Clark's (KMB) K-C Professional Unit Soft, Costs High
by Zacks Equity Research
Kimberly-Clark's (KMB) K-C Professional unit sales are declining year over year due to hurdles related to coronavirus. The company is also seeing escalated costs.
Zoom's (ZM) Q1 Earnings Top Estimates, Revenues Jump Y/Y
by Zacks Equity Research
Zoom's (ZM) first-quarter fiscal 2022 results reflect solid user growth, driven by coronavirus-led remote-working and online-learning wave.
Texas Roadhouse, Kimberly-Clark, HP, Interpublic Group of Companies and Foot Locker highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Texas Roadhouse, Kimberly-Clark, HP, Interpublic Group of Companies and Foot Locker highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Kimberly-Clark (KMB)
by Madeleine Johnson
The pandemic boost looks to be over for this consumer staples giant.
ACI vs. KMB: Which Stock Is the Better Value Option?
by Zacks Equity Research
ACI vs. KMB: Which Stock Is the Better Value Option?
ACI vs. KMB: Which Stock Is the Better Value Option?
by Zacks Equity Research
ACI vs. KMB: Which Stock Is the Better Value Option?
4 Consumer Products Stocks in Focus Despite Industry Headwinds
by Vrishali Bagree
The Zacks Consumer Products - Staples industry players are likely to see moderation in pandemic-led demand. Also, high costs are concerning, while solid saving plans and online sales keep Newell Brands (NWL), Tupperware Brands (TUP), Albertsons Companies (ACI) and Chewy (CHWY) well placed.
Kimberly-Clark (KMB) Q1 Earnings Miss Estimates, Decline Y/Y
by Zacks Equity Research
Kimberly-Clark's (KMB) first-quarter 2021 results reflect lower sales and earnings on softness in Consumer Tissue and K-C Professional units. Also, management updates its 2021 view.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Q1 Earnings Deluge Continues: AXP, HON, SLB, KMB & More
by Mark Vickery
A new capital gains tax proposal is adding to market malaise as Q1 earnings reports continue to hurtle down the pike.
Kimberly-Clark (KMB) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Kimberly-Clark (KMB) delivered earnings and revenue surprises of -5.26% and -4.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Kimberly-Clark (KMB) Might Surprise This Earnings Season
by Zacks Equity Research
Kimberly-Clark (KMB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Kimberly-Clark (KMB) Queued for Q1 Earnings: Factors to Note
by Zacks Equity Research
Kimberly-Clark's (KMB) first-quarter 2021 results are likely to reflect escalated costs and softness in the K-C Professional unit, though the Consumer Tissue segment should offer some respite.